<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melanoma: Epidemiology and risk factors</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melanoma: Epidemiology and risk factors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Melanoma: Epidemiology and risk factors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Clara Curiel-Lewandrowski, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Melanoma is the most serious form of skin cancer. The rapid increase in the incidence of melanoma and its associated mortality require a detailed understanding of the risk factors associated with melanoma.</p><p>Here we will review epidemiologic changes in the incidence and mortality, specific risk factors, and the management of patients at high risk for the development of melanoma. Primary prevention, screening, and techniques of skin examination are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15806.html" rel="external">"Melanoma: Clinical features and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H5112797"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of melanoma is rising dramatically worldwide, and mortality rates are beginning to decrease, likely due to increasing early detection efforts and significant breakthroughs in advanced melanoma treatment. Understanding the epidemiology provides information about important causative factors and prevention.</p><p>Melanoma is rare in children and adolescents, and approximately 90 percent of these cases are in those ≥10 years of age [<a href="#rid1">1-4</a>]. (See  <a class="medical medical_review" href="/d/html/101324.html" rel="external">"Melanoma in children", section on 'Epidemiology'</a>.)</p><p class="headingAnchor" id="H5112804"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Melanoma incidence is on the increase worldwide: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>United States</strong> – In the United States, melanoma is the fifth leading cancer in males and females [<a href="#rid5">5</a>]. An estimated 97,610 new cases of invasive melanoma and 89,070 cases of in situ melanoma will be diagnosed in the United States in 2023 [<a href="#rid6">6</a>]. In 2019, the annual incidence rate was 27 per 100,000 among non-Hispanic White Americans, 5 per 100,000 among Hispanic Americans, and 1 per 100,000 in Black Americans and Asian/Pacific Islander Americans [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Invasive melanoma incidence trends vary by age and sex. Rates among individuals younger than age 50 have stabilized in females and declined by approximately 1 percent per year in males since the early 2000s. However, for adults ages 50 and older, rates continued to increase in females by approximately 1 percent per year from 2015 to 2019 but have stabilized in males [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">A study performed in Olmsted County, Minnesota, that included patients aged 40 to 60 years with a first lifetime diagnosis of cutaneous melanoma between January 1, 1970, and December 31, 2020, found a nearly 12-fold increase in the age- and sex-adjusted incidence rate of melanoma between 1970 and 2020 (from 8.6 [95% CI 3.9-13.3] per 100,000 person-years in 1970 through 1979 to 99.1 [95% CI 89.5-108.7] per 100,000 person-years in 2011 through 2020) [<a href="#rid8">8</a>]. Of note, there was a 52-fold increase in females and a 6-fold increase in males.</p><p></p><p class="bulletIndent1">In contrast, trends in melanoma incidence were different for children, adolescents, and young adults. The incidence rates remained low and stable among children (age 0 to 9 years), while for both adolescents (age 10 to 19 years) and young adults (age 20 to 29 years), the incidence peaked at approximately 2004 to 2005 and then began to decrease [<a href="#rid9">9</a>]. Between 2006 and 2015, the incidence rate decreased among adolescent males and females by 4.4 percent (95% CI -1.7 to -7.0) and 5.4 percent (95% CI -3.3 to -7.4), respectively, and by 3.7 percent (95% CI -2.5 to -4.8) and 3.6 percent (95% CI -2.8 to -4.5) among young adult males and females, respectively. Overall, the number of reported cases of melanoma in adolescents and young adults decreased by 23.4 percent from 2006 to 2015 [<a href="#rid9">9</a>]. One hypothesis to explain this decreasing trend in melanoma incidence among persons younger than 30 years is that it may be related to a change in sun-protection behavior. However, as the national registry data do not include information on melanoma risk factors, such as skin pigmentation, ultraviolet (UV) light exposure, sunburn history, and sun-protective behavior, this hypothesis remains to be proven.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>World</strong> – In 2020, an estimated 325,000 persons (174,000 males and 151,000 females) worldwide were diagnosed as having melanoma, and approximately 57,000 persons (32,000 males and 25,000 females) died of the disease [<a href="#rid10">10</a>]. Of all newly diagnosed cases in 2020, 259,000 (79.7 percent) were persons older than 50 years of age, and of all deaths in 2020, 50,000 persons (87.7 percent) were older than 50 years of age.</p><p></p><p class="bulletIndent1">Large geographic variations existed across countries and world regions, with the highest incidence rates among males (42 per 100,000 person-years) and females (31 per 100,000 person-years) observed in Australia/New Zealand, followed by Western Europe (19 per 100,000 person-years for males and females), North America (18 per 100,000 person-years for males and 14 per 100,000 person-years for females), and Northern Europe (17 per 100,000 person-years for males and 18 per 100,000 person-years for females) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Europe</strong> – Between the early 1970s and 2000, the estimated incidence of melanoma in Central Europe increased from 3 to 4 cases/100,000 inhabitants per year to 10 to 15 cases/100,000 inhabitants per year [<a href="#rid11">11</a>]. An analysis of data from 18 European cancer registries showed that between 1995 and 2012 the incidence of both invasive and in situ melanoma increased annually by 4 and 7.7 percent, respectively, in males and by 3 and 6.3 percent, respectively, in females [<a href="#rid12">12</a>]. The overall increase in the incidence of invasive melanoma was predominantly due to an increase in the incidence of thin tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Australia</strong> – Data from the Queensland Cancer Registry for the period 1995 to 2014 confirmed that the incidence of melanoma in Queensland, Australia, is the highest in the world (72 per 100,000 per year) [<a href="#rid13">13</a>]. While the incidence of in situ melanoma increased over the 20-year period across all age groups, the incidence of invasive melanoma decreased among individuals under the age of 40 years, was stable in the age group 40 to 60 years, and increased among individuals older than 60 years. In 2021, it was estimated that the age-standardized incidence rate in Australia was 55 cases per 100,000 persons (67 for males and 45 for females) [<a href="#rid14">14</a>].</p><p></p><p>Some investigators have suggested that the reported increase in melanoma incidence results at least in part from of an increasing number of skin biopsies and significant variability in the histologic interpretation of early evolving lesions [<a href="#rid15">15</a>]. However, this explanation does not account for the increase in melanoma mortality rates, particularly in older males.</p><p>Others have speculated that the increasing incidence of melanoma is related to a rise in screening for melanoma, leading to the detection of thinner, more indolent lesions [<a href="#rid16">16</a>]. However, a study of Surveillance, Epidemiology, and End Results (SEER) data (1992 to 2004) from non-Hispanic White individuals found increasing incidence of melanoma of all thicknesses and among all socioeconomic levels [<a href="#rid17">17</a>]. Individuals of low socioeconomic status, who were believed to be less likely to have access to screening services, exhibited the highest increase in melanoma incidence when compared with subjects with higher socioeconomic status. In a study of a population-based screening program, the incidence of in situ and invasive melanomas in the screened population increased throughout the one-year screening period but returned to baseline levels in the three years after the screening program was discontinued [<a href="#rid18">18</a>]. In the control region, by contrast, a small increase in incidence was observed throughout the study period. These results suggest that screening accounts for some, but not all, of the increase in melanoma incidence.</p><p>Ongoing efforts to stratify screening for melanoma are seeking to reduce the burden of indolent disease diagnosis while focusing on the population at higher risk of invasive and advanced disease accounting for current mortality rates [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Geographic and ethnic variation</span><span class="headingEndMark"> — </span>The interplay of genetic and environmental risk factors likely accounts for the wide variation in melanoma incidence in different ethnic groups and geographic areas, as evidenced by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In an analysis of data from the SEER database from 2014 to 2018, the age-adjusted melanoma incidence rates in the United States in American Indian/Alaska Native, Asian/Pacific Islander, Black, Hispanic, and White individuals were 5.5, 1.3, 0.9, 4.9, and 32.2 per 100,000 individuals per year, respectively [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another analysis of data from the SEER database from 1975 to 2016, the most common sites for primary melanoma in patients with skin of color, except in patients of American Indian/Alaska Native descent, were the hips and lower limbs, including the soles [<a href="#rid22">22</a>]. For American Indian/Alaska Native and non-Hispanic White patients, the most common site for primary melanomas was the trunk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased incidence of melanoma is associated with an increased UV index and lower latitude only in non-Hispanic White persons. No evidence to support the association of UV exposure and melanoma incidence in Black or Hispanic populations was observed [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H55103868"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>In Australia, a trend towards a decrease in melanoma mortality rates between the late 1980s and 2002 was demonstrated for both males and females aged 35 to 54 years (-2.4 and -2.9 percent per year, respectively), whereas the rates remained stable for those aged 55 to 79 years [<a href="#rid24">24</a>]. In 2021, it was estimated that the age-standardized mortality rate was 4 deaths per 100,000 persons (5.6 for males and 2.6 for females) compared with the 2019 rate of 4.5 deaths per 100,000 persons (6.6 for males and 2.8 for females) [<a href="#rid14">14</a>]. An analysis of data from the Queensland Cancer Registry for the period 1995 to 2014 showed decreased or stable mortality rates in all age groups except in males aged 60 years or older [<a href="#rid13">13</a>]. </p><p>In the United States, the overall mortality from melanoma has declined rapidly over the past decade (2011 to 2020) by approximately 5 percent per year in adults younger than age 50 and 3 percent per year in those 50 and older because of advances in treatment. A total of 7990 deaths from the disease are expected in 2023 (5420 males and 2570 females) [<a href="#rid6">6</a>]. From 2007 to 2016, the death rate for melanoma declined by approximately 2 percent per year in adults 50 years of age and older and by approximately 4 percent per year in those younger than 50 [<a href="#rid7">7</a>]. The decline in mortality noted in younger patients may represent the effects of public education on early detection and treatment.</p><p>There are no clinical trials demonstrating that screening decreases the mortality from melanoma. However, five years after the completion of a screening program involving approximately 400,000 participants in Germany, the mortality rates from melanoma in the screened area were 50 percent lower than those observed in the nonscreened regions [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a>.) </p><p class="headingAnchor" id="H6"><span class="h1">ULTRAVIOLET RADIATION</span></p><p class="headingAnchor" id="H55104547"><span class="h2">Epidemiologic evidence</span><span class="headingEndMark"> — </span>Although a direct causal relationship between solar ultraviolet (UV) radiation and melanoma cannot be demonstrated experimentally, the evidence from indirect studies is overwhelming and leaves little doubt that UV exposure is a major risk factor for melanoma:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical and epidemiologic evidence demonstrates higher rates of melanoma in people with extensive or repeated intense exposure to sunlight. The majority of melanomas develop on sun-exposed skin, particularly in areas that are more susceptible to sunburn. Individuals with naturally dark skin or whose skin darkens easily upon sun exposure have lower rates of melanoma, supporting the concept that greater penetration of UV light into the skin results in a higher risk [<a href="#rid26">26</a>]. (See <a class="local">'Timing and pattern of sun exposure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major case-control studies assessing sun exposure, sunburn, and melanoma incidence were analyzed in a systematic review [<a href="#rid27">27</a>]. Intermittent exposure and sunburn in adolescence or childhood were strongly associated with an increased risk of melanoma, while occupational exposure did not confer an increased risk. These findings support the hypothesis that melanoma risk is affected primarily by intermittent intense sun exposure. (See <a class="local">'Timing and pattern of sun exposure'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjusted for skin type, the geographic incidence of melanoma is highest in equatorial areas and decreases proportionately with distance from the equator, with its correspondingly lower level of UV exposure [<a href="#rid28">28</a>]. Geographic variation in melanoma and nonmelanoma skin cancer rates is also documented in African Americans [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies strongly indicate that a decrease in recreational sun exposure following the diagnosis of primary melanoma, and thus a change in future individual behavior, can significantly diminish the chance of a second primary melanoma [<a href="#rid30">30,31</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Ultraviolet A versus ultraviolet B irradiation</span><span class="headingEndMark"> — </span>Ultraviolet B (UVB; wavelengths 290 to 320 nm) radiation appears more closely associated with the development of melanoma than ultraviolet A (UVA; wavelengths 320 to 400 nm). This is supported by the higher incidence of melanoma in equatorial regions than in latitudes farther from the equator, as UVB radiation is most intense at the equator while UVA intensity varies less across latitudes.</p><p>Although UVB appears to be more important than UVA as a risk factor, a causal link to UVA exposure is also supported by data from patients using tanning beds and/or treated with psoralen plus ultraviolet A (PUVA) for psoriasis. (See <a class="local">'Indoor tanning'</a> below and <a class="local">'Psoralen plus ultraviolet A therapy'</a> below.)</p><p class="headingAnchor" id="H3494124484"><span class="h2">Pathogenetic mechanisms</span><span class="headingEndMark"> — </span>Two independent pathogenetic pathways for UV-induced melanomagenesis have been postulated: a melanin-independent pathway associated with direct UVB-induced deoxyribonucleic acid (DNA) damage and a UVA-initiated, pigment-dependent pathway associated with indirect oxidative DNA damage in melanocytes [<a href="#rid32">32</a>]. UVB-induced mutations are typically cytosine-to-thymine transitions arising from cyclobutane pyrimidine dimers (CPDs) that are rapidly formed in the DNA as an effect of UVB irradiation. In contrast, UVA radiation generates CPDs in melanocytes for over three hours after exposure ("dark CPDs") by a mechanism that involves melanin, in particular pheomelanin, and reactive oxygen species as cofactors [<a href="#rid33">33</a>]. Furthermore, in experimental studies, both UVA and UVB radiation have been shown to accelerate <em>BRAF</em>-mediated melanomagenesis through <em>TP53</em> mutation [<a href="#rid34">34</a>]. Epigenetic modulators of melanogenesis and melanoma progression represent an active area of research, with microribonucleic acids (microRNAs), such as miR-21, identified to play a role in this process [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Timing and pattern of sun exposure</span><span class="headingEndMark"> — </span>The pattern and timing of sun exposure appear to be important for skin cancer. Nonmelanoma cancers are associated with cumulative sun exposure and occur most frequently in areas maximally exposed to the sun (eg, face, dorsal hands, forearms).</p><p>In contrast, melanomas tend to be associated with intense, intermittent sun exposure and sunburns, and they frequently occur in areas exposed to the sun only sporadically (eg, the back in males, the legs in females) [<a href="#rid36">36-39</a>]. This association with intermittent sun exposure may not be true for all body sites. For example, melanomas of the head and neck are more frequent in patients with high occupational sun exposure [<a href="#rid40">40,41</a>]. </p><p>Exposure early in life seems particularly important. Individuals who have had five or more severe sunburns in childhood or adolescence have an estimated twofold greater risk of developing melanoma [<a href="#rid36">36,42</a>]. Moreover, the incidence of melanoma is higher among people who migrate from northern to more equatorial latitudes; this effect is seen predominantly among those who were children at the time of migration [<a href="#rid43">43,44</a>].</p><p>It is not clear why intermittent extreme sun exposure appears to increase the risk of melanoma, whereas chronic suberythemogenic exposure is associated more with nonmelanoma skin cancer. After severe UV radiation-induced DNA damage, keratinocytes (from which squamous and basal cell carcinomas arise) undergo apoptosis or programmed cell death. In contrast, melanocytes are resistant to this level of radiation, and their survival results in the propagation of mutated genes, especially if damaged DNA is not fully repaired [<a href="#rid26">26,45</a>].</p><p>This may be an evolutionarily selected advantage for the organism, as the melanocytes survive a sunburn and can protect regenerating keratinocytes. However, on a cellular level, melanocytes that have suffered mutation of growth-regulating genes may have an unwanted growth advantage, resulting in disordered control of cell cycling and replication. Despite the high mortality associated with melanoma, the mechanisms that diminish melanocyte apoptosis may paradoxically be evolutionarily selected, as melanomas most often arise after the age of childbearing.</p><p class="headingAnchor" id="H9"><span class="h2">Indoor tanning</span><span class="headingEndMark"> — </span>In the 1920s, "sun therapy" gained popularity as a cure for multiple maladies. The French fashion designer Gabrielle "Coco" Chanel further glamorized the deep tan as a status symbol. Fifty years later, commercial tanning beds, which emit UVA light, became widespread. </p><p>Results from the United States 2010 National Health Interview Survey and 2011 <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fpdf%2Fss%2Fss6104.pdf&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLAYYkdjH6HWdFi7b%2BDaSf7UlPtSUfk1nbZk%2BIf%2FPL%2BrJ&amp;TOPIC_ID=4844" target="_blank">Youth Risk Behavior Survey</a> reveal that nearly one-third of White females aged 18 to 25 years reported indoor tanning in the past year, with approximately 15 percent engaging in frequent indoor tanning (≥10 sessions in the previous year) [<a href="#rid46">46,47</a>]. The analysis of data from the Health Information National Trends Survey, a mailed survey from the years 2007, 2011, 2013, 2014, 2017, and 2018, showed a substantial decrease of indoor tanning prevalence among adults (from 10 to 4 percent) and among young adults aged 18 to 34 years (14 to 4 percent) [<a href="#rid48">48</a>]. Indoor tanning decreased in states that enacted youth access legislation by 2018 but did not decrease for other states. </p><p>The reasons for the decline in the use of indoor tanning among high school students in the United States is incompletely understood. It is possible that multiple factors, including the acknowledgment of the role of UV-emitting tanning devices as a carcinogen to human skin by the World Health Organization [<a href="#rid49">49</a>], increased taxation on indoor tanning implemented in 2010, and restriction of minors from accessing indoor tanning in most states, may have increased the awareness of the health risks associated with indoor tanning in the general population.</p><p>A systematic review of 88 observational studies with nearly 500,000 participants from 16 Western countries found a summary prevalence of ever exposure to indoor tanning of 36 percent among adults, 55 percent among university students, and 19 percent among adolescents [<a href="#rid50">50</a>]. Regulations restricting the access to indoor tanning facilities to young individuals have been implemented worldwide; they are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma", section on 'Tanning bed use'</a>.)</p><p>Based upon evidence from multiple studies suggesting that tanning beds increase the risk of melanoma, in 2009 the World Health Organization International Agency for Research on Cancer (IARC) classified ultraviolet light emitted from tanning beds as a human carcinogen [<a href="#rid49">49,51</a>]. Subsequent observational studies and meta-analyses have confirmed the association between indoor tanning and melanoma [<a href="#rid52">52-55</a>]. Case-control studies have also found an association between tanning devices and ocular melanoma [<a href="#rid56">56-58</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2021 meta-analysis of 36 observational studies with 14,583 melanoma cases showed a significant association between indoor tanning and risk of melanoma (relative risk [RR] 1.27, 95% CI 1.16-1.39) [<a href="#rid59">59</a>]. Moreover, the risk was higher for first exposure at an early age (≤20 years) and higher exposure (annual frequency ≥10 times) (RR 1.47, 95% CI 1.16-1.85 and RR 1.52, 95% CI 1.22-1.89, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A population-based, case-control study including 681 patients with melanoma and 654 matched controls younger than 50 years found that females who had ever tanned indoors had a two- to sixfold increased risk of melanoma compared with females who had never tanned indoors [<a href="#rid60">60</a>]. Of note, among females aged 30 to 39 years and 40 to 49 years, indoor tanning was strongly associated with the risk of melanoma after controlling for known phenotypic and lifestyle risk factors for melanoma (OR 3.5, 95% CI 1.2-9.7 and OR 2.3, 95% CI 1.4-3.6, respectively). In all age groups, the risk was consistently increased for females who started tanning indoors before age 25 years and for those who reported &gt;10 lifetime tanning sessions.</p><p></p><p>The possibility that the association between tanning bed use and melanoma in fair-skinned individuals is overestimated due to residual confounding cannot be excluded. Tanning bed use may be a marker of populations more exposed to the sun. Studies have shown that tanning bed users are more likely to be regular sunbathers and to have poorer sun protection behavior than nonusers [<a href="#rid61">61,62</a>].</p><p>A common misconception about indoor tanning is that it may be helpful to prevent sunburn, a recognized risk factor for melanoma [<a href="#rid63">63</a>] (see  <a class="medical medical_review" href="/d/html/6624.html" rel="external">"Sunburn", section on 'Prevention'</a>). A reanalysis of data from a population-based, case-control study including more than 1800 participants examined the risk of melanoma associated with indoor tanning among individuals with and without history of sunburn [<a href="#rid64">64</a>]. In this analysis, among individuals who reported no lifetime sunburns, melanoma patients were almost four times more likely to have used tanning beds than controls, after adjusting for potential confounders (OR 3.87, 95% CI 1.68-8.91).</p><p class="headingAnchor" id="H10"><span class="h2">Psoralen plus ultraviolet A therapy</span><span class="headingEndMark"> — </span>Exposure to oral <a class="drug drug_general" data-topicid="9577" href="/d/drug information/9577.html" rel="external">methoxsalen</a> (psoralen) and ultraviolet A radiation (PUVA) used in the treatment of psoriasis and other skin conditions is associated with a late increase in the risk of melanoma. In a multicenter series of 1380 patients with severe psoriasis who were first treated with PUVA in 1975 and 1976, the incidence of invasive or in situ cutaneous melanomas was not elevated above that expected in the general population in the first 15 years following treatment. However, the incidence rate for all melanomas was increased fivefold between 16 and 20 years, and more than 12 times than expected beyond 20 years of follow-up [<a href="#rid65">65</a>]. The amount of PUVA treatment was also a factor; patients who received high doses of PUVA had a greater risk for melanoma.</p><p class="headingAnchor" id="H2716304517"><span class="h1">PHENOTYPIC TRAITS</span></p><p class="headingAnchor" id="H1615409604"><span class="h2">Skin pigmentation and tanning ability</span><span class="headingEndMark"> — </span>Light skin pigmentation, red or blond hair, blue or green eyes, freckling tendency, and poor tanning ability  (<a class="graphic graphic_table graphicRef60541" href="/d/graphic/60541.html" rel="external">table 1</a>), which reflect the skin sensitivity to sunlight, are well-known risk factors for melanoma. In a meta-analysis of observational studies, light skin phototype, blue eye color, red hair, and high freckle density were associated with a two- to fourfold increase in melanoma risk  (<a class="graphic graphic_table graphicRef105397" href="/d/graphic/105397.html" rel="external">table 2</a>) [<a href="#rid66">66</a>]. </p><p class="headingAnchor" id="H12"><span class="h2">Common (typical) nevi</span><span class="headingEndMark"> — </span>Although some nevi are precursors to cutaneous melanoma, they are more often markers of increased risk [<a href="#rid67">67</a>], as only approximately one-third of melanomas arise from pre-existing nevi [<a href="#rid68">68</a>]. Common nevi are usually ≤5 mm in diameter and can be raised or flat with a round shape and uniform color  (<a class="graphic graphic_picture graphicRef73384" href="/d/graphic/73384.html" rel="external">picture 1</a>). Most of these nevi occur in photo-exposed areas.</p><p class="headingAnchor" id="H13"><span class="h3">Number of nevi</span><span class="headingEndMark"> — </span>Studies have supported a strong association of high total body nevus counts with melanoma  (<a class="graphic graphic_table graphicRef105397" href="/d/graphic/105397.html" rel="external">table 2</a>) [<a href="#rid69">69-72</a>]. The relative risk (RR) of melanoma that is associated with high total nevus counts ranges from 1.6 to 64 with a dose-response effect based upon the number of nevi present (including routine junctional, compound, and dermal nevi) [<a href="#rid73">73-76</a>]. The number most often cited as the cut-off for increased melanoma risk is 50 to 100 nevi, which is associated with an RR of 5 to 17 [<a href="#rid77">77,78</a>]. However, a meta-analysis of observational studies found that increased risk may be present in individuals with more than 25 nevi [<a href="#rid79">79</a>]. In this study, 42 percent of melanoma cases were attributable to having ≥25 typical nevi (population attributable fraction [PAF] = 0.15). Lower nevus counts were less strongly associated with melanoma (PAF for 0 to 10 nevi = 0.04, PAF for 11 to 24 nevi = 0.07). </p><p>The number of nevi on one arm appears to be predictive of the total body nevus. In a United Kingdom study involving 3694 female twins with a median age of 47 years, females with &gt;11 nevi on the right arm were approximately nine times more likely to have a total body count of &gt;100 nevi (odds ratio [OR] 9.4, 95% CI 6.7-13.1) [<a href="#rid80">80</a>]. </p><p class="headingAnchor" id="H1004018845"><span class="h3">"Divergent pathway" model</span><span class="headingEndMark"> — </span>The "divergent pathway" model describes the theory that individuals with the propensity to develop fewer melanocytic nevi require greater sun exposure to promote the development of melanoma, and tend to develop melanoma on chronically sun-exposed sites (eg, head or neck) [<a href="#rid69">69,70,81,82</a>]. Conversely, individuals with large numbers of nevi may require less solar stimulation to drive the development of melanoma and are prone to develop melanoma in sites where large numbers of nevi are found, such as the back. This "divergent pathway" model suggests that melanomas on different sites of the body may occur via different mechanisms.</p><p>A meta-analysis of 24 observational studies found that high nevus counts were more strongly associated with the development of melanoma on the legs or trunk (RR 1.79, 95% CI 1.56-2.06 and RR 1.67, 95% CI 1.45-1.92, respectively) when compared with anatomical sites associated with chronic sun exposure, such as the head or arms (RR 1.42, 95% CI 1.23-1.64 and RR 1.60, 95% CI 1.39-1.83, respectively) [<a href="#rid72">72</a>]. In addition, a pooled analysis of ten case-control studies (2406 female melanoma patients and 3119 female controls) identified a statistically significant trend indicating an association of increasing numbers of nevi with melanoma on the trunk and limbs, but not with melanoma of the head and neck [<a href="#rid70">70</a>]. The RRs for melanoma in females with high numbers of nevi compared with females with no nevi were reported as highest for melanoma on the trunk (OR 4.6, 95% CI 2.7-7.6) and limbs (OR 3.4, 95% CI 1.5-7.9), followed by the head and neck (OR 2.0, 95% CI 0.9-4.5).</p><p>Although advances have shed much light on the mechanisms linking nevi and melanoma, many questions remain. In particular, imaging, genetics, and cognitive computing have enormous potential to stratify risk categories, but protocols for integrating them into regular clinical care are still in the developmental stage [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Congenital nevi</span><span class="headingEndMark"> — </span>Congenital melanocytic nevi (CMN) are classically defined as melanocytic nevi present at birth or within the first few months of life. These occur in 1 to 2 percent of newborn infants, and large or giant CMN occur in approximately 1 of 20,000 births. For patients with large CMN, the risk of developing melanoma (cutaneous or extracutaneous) is estimated to be approximately 2 to 5 percent over a lifetime, with most melanomas occurring in the first five years of life [<a href="#rid84">84</a>].</p><p>The clinical features, complications, and management of CMN are discussed separately. (See  <a class="medical medical_review" href="/d/html/4847.html" rel="external">"Congenital melanocytic nevi"</a>.)</p><p class="headingAnchor" id="H3231403696"><span class="h2">Atypical nevi</span><span class="headingEndMark"> — </span>Atypical nevi are benign, acquired melanocytic neoplasms that share some of the clinical features of melanoma, such as asymmetry, irregular borders, multiple colors, and diameter &gt;5 mm. The terms "atypical nevi" and "dysplastic nevi" are clinically used interchangeably, although in theory a dysplastic nevus refers to a histologic diagnosis. Although atypical nevi are benign lesions, they are strong phenotypic markers of an increased risk of melanoma, especially in individuals with numerous nevi and/or a family history of melanoma  (<a class="graphic graphic_table graphicRef105397" href="/d/graphic/105397.html" rel="external">table 2</a>). In a meta-analysis of observational studies, the RR of melanoma associated with atypical nevi was 1.5 (95% CI 1.3-1.6) for the presence of a single atypical nevus and 6.36 (95% CI 3.80-10.33) for five atypical nevi versus none [<a href="#rid85">85</a>].</p><p>The clinical features, diagnosis, and management of atypical nevi are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/13519.html" rel="external">"Atypical (dysplastic) nevi"</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">FAMMM syndrome and atypical mole syndrome</span><span class="headingEndMark"> — </span>Some familial cases of melanoma occur in the setting of the familial atypical multiple mole and melanoma (FAMMM) syndrome and the atypical mole syndrome. The FAMMM syndrome was originally described in families showing concordance for malignant melanoma and a cutaneous phenotype characterized by multiple large moles of variable size and color (reddish-brown to bright red) with pigmentary leakage [<a href="#rid86">86,87</a>]. Their lifetime cumulative incidence of melanoma approached 100 percent.</p><p>The atypical mole syndrome (sometimes also called the dysplastic nevus syndrome) refers to patients who have 50 to 100 or more nevi, at least one of which is ≥8 mm in diameter, and at least one with atypical features, without personal or family history of melanoma [<a href="#rid88">88</a>]. (See  <a class="medical medical_review" href="/d/html/13519.html" rel="external">"Atypical (dysplastic) nevi"</a>.)</p><p class="headingAnchor" id="H55103422"><span class="h1">PERSONAL HISTORY OF MELANOMA</span><span class="headingEndMark"> — </span>A personal history of melanoma is associated with a higher risk of developing a second primary cutaneous and noncutaneous melanoma  (<a class="graphic graphic_table graphicRef105397" href="/d/graphic/105397.html" rel="external">table 2</a>) [<a href="#rid89">89-94</a>]. A population-based study using data from the Swedish Cancer Registry from 1958 to 2010 found that patients with either familial or sporadic melanoma have a two- to threefold increased risk of a subsequent melanoma and that the risk remains stable for patients with two or more previous melanomas [<a href="#rid95">95</a>]. An additional population-based study in the United States has shown that individuals with prior cutaneous melanoma were more likely to develop a second cutaneous melanoma (standardized incidence ratio [SIR] 8.17, 95% CI 8.01-8.33), ocular melanoma (SIR 1.99, 95% CI 1.54-2.53), oral melanoma (SIR 6.87, 95% CI 2.23-16.04), and vaginal/exocervical melanoma (SIR 10.17, 95% CI 4.65-19.30) [<a href="#rid93">93</a>]. </p><p>Although the risk is highest in the first year after the initial diagnosis, it persists over time, and estimates of the risk of developing a second melanoma have ranged from 2 to 11 percent at five years [<a href="#rid90">90,94,96</a>]. In a study of 2253 patients with primary melanoma from the German Central Malignant Melanoma Registry, 146 patients (6.5 percent) developed a second primary melanoma during a median follow-up time of 73 months; in 70 patients (3 percent), a second primary tumor was detected in the first year of follow-up, and in 39 patients (1.7 percent) in the first 30 days [<a href="#rid97">97</a>]. The risk is similar for patients whose first primary cancer was either in situ or invasive melanoma [<a href="#rid96">96</a>].</p><p>Patient characteristics may influence the probability of developing additional lesions. For individuals with a history of both dysplastic nevi and cutaneous melanoma, the risk of a second primary lesion is greater than for those with a sporadic cutaneous melanoma [<a href="#rid98">98</a>].</p><p>Age and lesion site also may be markers for increased risk. In one population-based study, patients who were less than 30 years of age at the time of the initial diagnosis or who had a history of melanoma on the head or neck had a greater risk for developing a second primary lesion than other melanoma survivors [<a href="#rid89">89</a>]. An analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2006 on 551 adolescents and young adults with an invasive first primary melanoma and subsequent primary melanoma and 38,110 adolescents and young adults with only a first primary melanoma found that non-Hispanic White ethnicity, younger age at first diagnosis of melanoma, and female sex were associated with an increased risk of developing a subsequent melanoma [<a href="#rid99">99</a>].</p><p>High nevus counts, strong family history of melanoma (melanoma in more than one first-degree relative), and melanoma type also affect the risk of developing additional primary melanoma [<a href="#rid100">100</a>]. In a cohort of 1083 melanoma patients who were followed for more than 16 years, the hazard ratios (HR) for developing a second primary melanoma were highest for patients with high nevus counts (HR 2.91, 95% CI 1.94-4.35), strong family history of melanoma (HR 2.12, 95% CI 1.34-3.36), and for patients having lentigo maligna melanoma (HR 1.80, 95% CI 1.05-3.07) or nodular melanoma (HR 2.13, 95% CI 1.21-3.74) as the first primary melanoma [<a href="#rid100">100</a>].</p><p>Data obtained from the SEER registry from 1973 to 2006 indicate that compared with first melanomas, second melanomas tend to be thinner at the time of diagnosis (78 versus 70 percent &lt;1 mm in depth) [<a href="#rid89">89</a>]. The authors of this study speculated that increased clinical surveillance and/or patient awareness following the initial diagnosis may have contributed to this finding. A general trend towards earlier detection of melanoma also may have been a factor [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/d/html/4845.html" rel="external">"Screening for melanoma in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H55103208"><span class="h1">GENETIC BACKGROUND</span><span class="headingEndMark"> — </span>Approximately 10 percent of melanomas are familial [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma"</a>.)</p><p>Among subjects from melanoma families, defined as kindreds in which melanoma occurred in two or more blood relatives, the likelihood of developing melanoma is even greater among those family members who have dysplastic nevi [<a href="#rid103">103,104</a>]. In a subset of these kindreds, the apparent familial pattern of inheritance may be attributable to clustering of sporadic cases in families who share common heavy sun exposure and susceptible skin type, making genetic analysis and risk stratification more challenging. This concept is substantiated by studies in which <em>CDKN2A</em> mutation status, sun exposure, and prevalence of dysplastic/benign nevi influence melanoma risk in families unselected for family history as well as melanoma-prone families [<a href="#rid76">76</a>].</p><p>There appears to be considerable genetic heterogeneity among different families, suggesting that multiple genes contribute to melanoma predisposition [<a href="#rid105">105</a>]. Molecular defects in both tumor suppressor genes and oncogenes have been linked to familial melanoma:</p><p class="bulletIndent1"><span class="glyph">●</span>The major gene resides on chromosome 9p and encodes the tumor suppressor gene <em>CDKN2A</em>, also called p16INK4A or <em>MTS1</em> (multiple tumor suppressor-1). Increased frequency of <em>CDKN2A</em> mutations is associated with multiple cases of melanoma in a family, early age at diagnosis, and family members with multiple primary melanomas or pancreatic cancer [<a href="#rid106">106,107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The melanocortin-1 receptor (<em>MC1R</em>) gene, located on chromosome 16q24, is a key regulator of skin pigmentation. Variants of <em>MC1R</em> are associated with the red hair/fair skin phenotype, a known risk factor for melanoma [<a href="#rid108">108</a>]. However, some <em>MC1R</em> variants may carry an increased risk of melanoma independently from phenotypic characteristics and sun exposure [<a href="#rid109">109,110</a>]. In a case-control study including 991 patients with melanoma and 800 controls, carriers of two or more <em>MC1R </em>variants had an approximately twofold increased risk of melanoma, compared with wild type carriers, after adjusting for age, sex, number of sunburns before age 20, and signs of actinic skin damage [<a href="#rid111">111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>BAP1</em> mutations with a propensity for uveal (in 25 percent of carriers) and cutaneous melanomas (in 17 percent of carriers) and other internal malignancies have been described in an autosomal dominant tumor predisposition syndrome. Patients in this cohort might present with benign and/or atypical nevi phenotypes. Histologic assessment of cutaneous melanomas in this group has demonstrated spitzoid and nevoid features [<a href="#rid112">112-115</a>]. (See  <a class="medical medical_review" href="/d/html/129132.html" rel="external">"BAP1-inactivated melanocytoma"</a>.)</p><p></p><p>A comprehensive review of the melanoma susceptibility genes is presented separately. (See  <a class="medical medical_review" href="/d/html/7624.html" rel="external">"Inherited susceptibility to melanoma"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">HISTORY OF NONMELANOMA SKIN CANCER</span><span class="headingEndMark"> — </span>Individuals who have had basal cell or squamous cell skin carcinomas appear to have not only an increased risk of developing melanoma, but also an increased risk of dying from it [<a href="#rid116">116,117</a>].</p><p class="headingAnchor" id="H21"><span class="h1">IMMUNOSUPPRESSION</span><span class="headingEndMark"> — </span>De novo melanoma occurs with increased frequency in immunosuppressed patients, including organ transplant recipients, patients with lymphoma, and patients with human immunodeficiency virus (HIV) infection, and is associated with a poorer prognosis [<a href="#rid118">118,119</a>]. A population-based study of approximately 90,000 renal transplant recipients in the United States followed over a 10-year period, identified 246 patients with melanoma and a 3.6 times greater likelihood for the development of melanoma in organ transplant recipients compared with the general population [<a href="#rid120">120</a>]. This finding has been confirmed in an analysis of data from a cohort of over 105,000 renal transplant recipients from the United States Renal Data System database (years 2004 through 2012) [<a href="#rid121">121</a>]. The prevalence of melanoma in this cohort was 0.5 percent, with a standardized incidence ratio of 4.9 compared with the Surveillance, Epidemiology, and End Results population.</p><p>Among patients with melanoma treated before transplantation, recurrences are frequent (19 percent in one series), and usually occur within five years [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>.)</p><p class="headingAnchor" id="H323535278"><span class="h1">OTHER PROPOSED RISK FACTORS</span><span class="headingEndMark"> — </span>A number of other factors, including occupational exposures and lifestyle factors, have been evaluated as possible risk factors for melanoma [<a href="#rid123">123</a>].</p><p class="headingAnchor" id="H937180000"><span class="h2">Occupational</span><span class="headingEndMark"> — </span>Occupational exposure to chemicals has been examined in a number of studies focusing on polychlorinated biphenyls (PCBs), petroleum products, ionizing radiation, and <a class="drug drug_general" data-topicid="9884" href="/d/drug information/9884.html" rel="external">selenium</a> [<a href="#rid124">124</a>]. Although initial analyses showed patterns of increased incidence, no statistically significant occupational risk factors were found after adjustment for known risk factors such as nevus count and sun exposure.</p><p class="headingAnchor" id="H811375844"><span class="h2">Dietary</span><span class="headingEndMark"> — </span>Studies addressing the role of dietary factors (eg, antioxidants, retinoids, vitamin C, and vitamin E) have not shown a consistent impact of diet on the incidence of melanoma [<a href="#rid125">125,126</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin D</strong> – The role of vitamin D in the development of melanoma is controversial. A case-control study has suggested that diets rich in vitamin D and carotenoids and low in alcohol may be associated with a reduced risk for melanoma [<a href="#rid127">127</a>]. Another small, case-control study found an association between low blood levels of vitamin D (≤20 ng/ml) and melanoma risk [<a href="#rid128">128</a>]. However, a large, Mendelian, randomization study using data from a large, genome-wide association study meta-analysis of melanoma risk (12,874 cases and 23,203 controls of European ancestry) on five single nucleotide polymorphisms associated with plasma levels 25(OH)D found no association between genetically determined low levels of vitamin D and melanoma risk [<a href="#rid129">129</a>]. (See  <a class="medical medical_review" href="/d/html/13514.html" rel="external">"Mendelian randomization"</a> and  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma", section on 'Dietary vitamin D'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol</strong> – A meta-analysis of 16 case-control and cohort studies including over 6000 patients found a modest increase in melanoma risk associated with moderate to high alcohol drinking compared with no or occasional drinking (relative risk [RR] 1.20, 95% CI 1.06-1.37). The risk was 55 percent higher for individuals drinking 50 g of alcohol per day. However, these results should be interpreted with caution, since residual confounding by sun exposure cannot be excluded [<a href="#rid130">130</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Coffee</strong> – The association between coffee and tea intake and melanoma is controversial. Of note, in multiple meta-analyses of large observational studies, a protective association has been found for caffeinated coffee but not for decaffeinated coffee [<a href="#rid131">131-134</a>]. Proposed mechanisms of action of caffeine and other bioactive compounds present in regular coffee in preventing melanoma are based upon in vitro and animal studies but remain unproven in humans [<a href="#rid135">135,136</a>].</p><p></p><p class="bulletIndent1">A 2016 meta-analysis including two case-control and five cohort studies including nearly 850,000 participants found a modest inverse association between coffee intake and melanoma, with a pooled RR of 0.81 (95% CI 0.68-0.97) for highest versus lowest consumption of caffeinated coffee [<a href="#rid131">131</a>]. The study found a linear dose-response relationship between melanoma risk and level of coffee intake; the risk was reduced by 4.5 percent for one cup per day increment of caffeinated coffee intake compared with no consumption. In a stratified analysis, the protective effects of caffeinated coffee were significant in females (RR 0.76, 95% CI 0.61-0.95) but not in males (RR 1.11, 95% CI 0.91-1.36). No effect was found for decaffeinated coffee.</p><p></p><p class="bulletIndent1">A subsequent analysis of data from a large cohort from 10 European countries including nearly 500,000 individuals aged 25 to 70 years participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study confirmed an inverse association between caffeinated coffee and melanoma [<a href="#rid137">137</a>]. In this analysis, the consumption of caffeinated coffee or tea was associated with a decrease in melanoma risk among males but not among females (hazard ratio [HR] 0.31, 95% CI 0.14-0.69 and HR 0.96, 95% CI 0.62-1.47, respectively), after adjusting for education, smoking habit, alcohol intake, diet, body mass index, reproductive history, and use of exogenous hormones. No association was found for decaffeinated coffee or tea. However, the significance of these results remains uncertain because data on known risk factors for melanoma, including light phenotype, number of nevi, family history of melanoma, and ultraviolet radiation exposure, were not available for the participants in this study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Citrus fruit</strong> – An analysis of data from over 100,000 individuals participating in the Nurse's Health Study found a modest increase in melanoma risk associated with high dietary intake of citrus fruit or juice (HR 1.36, 95% CI 1.14-1.63), after adjusting for recognized risk factors for melanoma, such as family history of melanoma-phenotypic characteristics, number of nevi, and lifetime number of blistering sunburns [<a href="#rid138">138</a>]. A potential explanation for the association between melanoma and citrus fruit consumption is that citrus fruits are a source of psoralens, chemical compounds present in plants known to be photosensitizers [<a href="#rid139">139</a>]. However, the results of this study need further confirmation, because, given the small increase in risk, residual confounding cannot be excluded. In the meantime, changes in dietary advice to the public are not warranted.</p><p></p><p class="headingAnchor" id="H611327513"><span class="h2">Smoking</span><span class="headingEndMark"> — </span>Although skin changes may be related to smoking, smoking has not been found to be an independent risk factor for melanoma [<a href="#rid140">140</a>]. One study suggested an inverse relationship between smoking and melanoma in males [<a href="#rid141">141</a>].</p><p class="headingAnchor" id="H4242186999"><span class="h2">Oral contraceptives and postmenopausal hormone therapy</span><span class="headingEndMark"> — </span>Multiple studies have assessed the risk of melanoma associated with oral contraceptive pills, with some finding an elevated risk, particularly with prolonged use. However, two meta-analyses of observational studies showed no evidence for an increased risk of melanoma with the use of oral contraceptive pills [<a href="#rid142">142,143</a>]. Posthoc analysis of the Women's Health Initiative trials on postmenopausal hormone therapy found no increased risk of melanoma with hormone therapy [<a href="#rid144">144</a>]. An EPIC cohort study found a weak, statistically nonsignificant association between oral contraceptive pill or hormone therapy use and melanoma risk [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H4022797269"><span class="h2">Drugs</span><span class="headingEndMark"> — </span>Several drugs have been associated with increased risk of melanoma:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor necrosis factor inhibitors</strong> – A connection between tumor necrosis factor (TNF)-alpha inhibitors and melanoma was initially suggested by a few case reports [<a href="#rid146">146-149</a>]. A 2011 systematic review and meta-analysis of two studies from cancer registries found an increased risk of melanoma associated with TNF (RR 1.79, 95% CI 0.92-2.67) [<a href="#rid150">150</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BRAF inhibitors</strong> – Case reports have been published describing secondary cutaneous melanoma in patients treated with BRAF inhibitors alone or in combination with MEK inhibitors. It is unclear if this association is based on a direct BRAF inhibition effect or due to the identification of synchronous melanomas that might have already been present at the time treatment was initiated [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sildenafil</strong> – A study of nearly 26,000 males participating in the Health Professionals Follow-Up Study, followed up from 2000 to 2010, found an association between <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a> (a phosphodiesterase-5 [PDE5] inhibitor used to treat erectile dysfunction) and invasive melanoma after controlling for potential melanoma risk factors, such as age, number of moles, and severe sunburns (HR 1.84, 95% CI 1.04-3.22) [<a href="#rid152">152</a>]. However, this finding must be interpreted with caution because of the lack of control for other confounders (eg, health status, lifestyle practices) and lack of information about the dose, frequency, and duration of sildenafil use or the use of other PDE5 inhibitors.</p><p></p><p class="bulletIndent1">A modest 14 to 30 percent increase in risk of melanoma for males who had at least one prescription of a PDE5 inhibitor was also found in a nested case-control study in the Swedish Prescribed Drug Register and the Swedish Melanoma Register including over 4000 males with a diagnosis of melanoma and 20,000 cancer-free male controls [<a href="#rid153">153</a>]. However, the absence of a dose-response effect for PDE5 inhibitors and the lack of information on important personal and lifestyle-related melanoma risk factors raise the question on whether this association is causal.</p><p></p><p class="bulletIndent1">Finally, a large population-based matched cohort study using the United Kingdom Clinical Practice Research Datalink and including over 145,000 males with ≥1 PDE5 inhibitor prescription and 560,000 unexposed matched controls found only a weak association between PDE5 inhibitor use and incidence of melanoma (HR 1.14, 95% CI 1.01-1.29) [<a href="#rid154">154</a>]. However, the study found a similar weak association of PDE5 inhibitors with basal cell carcinoma and actinic keratosis but not colorectal cancer. These findings, in addition to the absence of a dose-response effect between PDE5 inhibitors and melanoma and the lack of information on personal sun exposure habits, suggest that the association between PDE5 inhibitors and melanoma is likely explained by the confounding effect of sun exposure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Voriconazole</strong> – Melanoma in situ has been reported in two patients during long-term therapy with <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a>, an antifungal drug that has been associated with cutaneous photosensitivity and squamous cell carcinoma [<a href="#rid155">155</a>]. Additional studies are necessary to determine whether there is an association between melanoma and this drug.</p><p></p><p class="headingAnchor" id="H264197690"><span class="h2">Parkinson disease</span><span class="headingEndMark"> — </span>Parkinson disease (PD) has been associated with an increased risk for melanoma [<a href="#rid156">156-159</a>]. </p><p>An epidemiologic study involving more than 14,000 patients with PD found a statistically significant increase in the incidence of melanoma in this population compared with the general population (standardized incidence ratio 1.95, 95% CI 2.4-2.6) [<a href="#rid156">156</a>]. </p><p>A Swedish, population-based, register study assessed the risk of melanoma in a cohort of approximately 12,000 patients with PD and in a matched cohort of approximately 60,000 PD-free individuals [<a href="#rid160">160</a>]. The risk of melanoma was also evaluated in approximately 17,000 siblings of PD patients and 84,000 siblings of PD-free individuals. PD patients had a 60 percent higher risk of melanoma than PD-free individuals (HR 1.61, 95% CI 1.35-1.92). In contrast, the risk of melanoma was similar in siblings of PD patients and in those of PD-free individuals.</p><p>A retrospective, United States study using data from the Rochester Epidemiology Project (REP) medical records from 1976 to 2013 identified a cohort of 974 PD patients, of whom 26 had a diagnosis of melanoma preceding the diagnosis of PD, whereas 6 had a melanoma following the diagnosis of PD [<a href="#rid161">161</a>]. Compared with controls, PD patients had a 3.8-fold increased likelihood of having a history of melanoma. Patients with melanoma identified from the same database had a 4.2-fold increased risk of developing PD after the diagnosis of melanoma compared with controls. While these findings suggest that melanoma and PD may share environmental or genetic risk factors, the underlying cause of this association remains to be clarified.</p><p>Although early case reports mentioned levodopa (a common therapy for PD) as a potential etiologic factor [<a href="#rid162">162</a>], an increased risk for melanoma precedes the diagnosis and treatment of the neurologic disorder [<a href="#rid157">157</a>]. In addition, a systematic review and a subsequent case-control study found no association between melanoma and this drug [<a href="#rid162">162,163</a>]. </p><p class="headingAnchor" id="H1037080941"><span class="h2">Other disease association</span><span class="headingEndMark"> — </span>There are reports of increased melanoma risk associated with other conditions, including endometriosis and prostate cancer:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endometriosis</strong> – A prospective, epidemiologic study has shown a statistically significant increase of melanoma in females with endometriosis (RR 1.6) [<a href="#rid164">164</a>]. Smaller, retrospective studies have observed a similar relationship [<a href="#rid165">165</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>History of prostate cancer</strong> – The United States Health Professionals' Follow-Up Study, including over 40,000 participants, found that a personal history of prostate cancer was associated with an increased risk of melanoma (HR 1.83, 95% CI 1.32-2.54, adjusted for age, body mass index, smoking, use of <a class="drug drug_general" data-topicid="9643" href="/d/drug information/9643.html" rel="external">sildenafil</a>, skin phototype, nevus count, family history of melanoma, and history of sun exposure) [<a href="#rid166">166</a>]. The underlying mechanism of this association is unknown. Further studies are needed to confirm the hypothesis of a potential role for androgens in the etiology of melanoma.</p><p></p><p class="headingAnchor" id="H3027204093"><span class="h1">RISK PREDICTION MODELS</span><span class="headingEndMark"> — </span>Risk prediction models provide a single personalized assessment of an individual's risk based on a combination of melanoma risk factors (rather than relying on multiple individual risk factors) and may assist clinicians in matching preventive interventions to risk levels.<strong> </strong>With increasing computational capability to process a large amount of data, one approach has been to generate melanoma risk prediction models in melanoma risk assessment to aid in management decisions. Optimally, these models can be integrated into the clinical workflow and eventually into reliable artificial intelligence algorithms and electronic medical records to maximize risk-appropriate management and patient education.</p><p class="bulletIndent1"><span class="glyph">●</span>A prediction model developed based on the "Australian Study" data identified total number of nevi ≥2 mm, solar lentigines on the upper back, hair color at age 18 years, and personal history of keratinocyte cancer as the lead criteria to include in the model [<a href="#rid167">167</a>]. The area under the curve (AUC) was 0.79 (95% CI 0.76-0.83) on internal validation in the "Australian Study" and 0.73 (95% CI 0.70-0.75) on subsequent external validation in the "Leeds Study." The authors concluded that the model may be useful for offering tailored preventive interventions, such as sun protection advice and skin screening based on personal risk level, in primary care and other clinical settings where dermatologic risk factors can be assessed. Prospective evaluation of the clinical risk prediction model will be needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prediction model to assess the risk of developing subsequent melanomas was developed based on the New South Wales Genes, Environment, and Melanoma case-control study database in which controls had single primary melanomas and cases had multiple primary melanomas [<a href="#rid168">168</a>]. A total of 1266 participants with 2613 melanomas were included in the analysis. The final model comprises 12 of the 21 initially considered risk factors, resulting in good discrimination for predicting a second melanoma (Harrell's C-statistic 0.73) and moderate discrimination (0.65) for predicting a third or fourth melanoma. The model showed a strong upward linear trend in the risk of subsequent melanoma across risk-score quintiles. The risk of a subsequent primary melanoma was substantially higher for people with two or more melanomas than for people with one (mean absolute risk 47 versus 8 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An attempt to perform a systematic review of prediction models for melanoma based on study characteristics, differences in risk factor selection and assessment, evaluation, and validation methods identified 40 studies comprising 46 different risk prediction models eligible for the review [<a href="#rid169">169</a>]. However, due to the substantial heterogeneity in risk factor selection and assessment (as well as methodologic aspects of model development) among the included studies, direct comparison was not feasible. The authors identified a total of 35 different risk factors across models, with nevi being the most common one <em>in 35 studies</em> (87 percent); minimal consistency in other risk factors was observed. Results of an internal validation were reported for less than one-half of the studies (<em>n =</em> 18, 45 percent), and only six performed external validation. In terms of model performance, 29 studies assessed the discriminative ability of their models. The authors stated that uniform methodologic standards for the development and validation of risk prediction models for melanoma and reporting standards for the accompanying publications are necessary and should be required.</p><p></p><p class="headingAnchor" id="H3471541745"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H28"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15739.html" rel="external">"Patient education: Sunburn (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15499.html" rel="external">"Patient education: Melanoma skin cancer (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2730.html" rel="external">"Patient education: Sunburn (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/889.html" rel="external">"Patient education: Melanoma treatment; localized melanoma (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/892.html" rel="external">"Patient education: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1907897"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence and mortality</strong> – The incidence of melanoma has increased rapidly over the years. The estimated age-standardized incidence rates of melanoma in males and females worldwide increased from 2.3 and 2.2/100,000 people, respectively, in 1990 to 3.1 and 2.8/100,000 people, respectively, in 2008. In the United States, melanoma is the fifth most common cancer in males and females. In Australia, the estimated age-standardized mortality rate in 2021 was 4 deaths per 100,000 persons. (See <a class="local">'Epidemiology'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ultraviolet radiation and patterns of exposure</strong> – Evidence suggests that ultraviolet radiation is a major risk factor for melanoma. Although ultraviolet B (UVB) radiation plays a greater role in the development of melanoma, exposure to ultraviolet A radiation (including tanning beds and psoralen plus ultraviolet A radiation [PUVA] therapy) also appears to be a risk factor. (See <a class="local">'Ultraviolet radiation'</a> above.)</p><p></p><p class="bulletIndent2">Melanoma tends to be associated with a history of intense, intermittent sun exposure and most frequently occurs on areas that are exposed to the sun sporadically, such as the back in males and legs in females. However, chronic sun exposure may contribute to the development of melanoma on other sites, such as the head and neck. A history of multiple severe sunburns in childhood is also associated with increased melanoma risk. (See <a class="local">'Timing and pattern of sun exposure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indoor tanning</strong> – The results of several studies have implicated tanning beds as a risk factor for melanoma. In 2009, the World Health Organization classified ultraviolet light emitted from tanning beds as a human carcinogen. Ultraviolet A therapy with high doses of psoralens (PUVA) has also been identified as a risk factor for melanoma. (See <a class="local">'Indoor tanning'</a> above and <a class="local">'Psoralen plus ultraviolet A therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phenotypic traits and genetic background</strong> – Patient-specific factors influence the risk for melanoma. High numbers of typical nevi, the presence of atypical nevi, a personal history of melanoma, and genetic factors can increase risk. Patients with the familial atypical multiple mole and melanoma (FAMMM) syndrome have a risk of melanoma much greater than that of the general population. (See <a class="local">'Common (typical) nevi'</a> above and <a class="local">'Atypical nevi'</a> above and <a class="local">'Personal history of melanoma'</a> above and <a class="local">'Genetic background'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Counseling for high-risk patients</strong> – Patients at high risk for melanoma should be counseled about sun protection and skin self-examination and should be followed with periodic dermatologic evaluation, including dermoscopy and digital imaging where available, according to melanoma risk stratification protocols. (See  <a class="medical medical_review" href="/d/html/4842.html" rel="external">"Primary prevention of melanoma"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2005; 23:4735.</a></li><li><a class="nounderline abstract_t">Lange JR, Palis BE, Chang DC, et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007; 25:1363.</a></li><li><a class="nounderline abstract_t">Austin MT, Xing Y, Hayes-Jordan AA, et al. Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States. J Pediatr Surg 2013; 48:2207.</a></li><li><a class="nounderline abstract_t">Campbell LB, Kreicher KL, Gittleman HR, et al. Melanoma Incidence in Children and Adolescents: Decreasing Trends in the United States. J Pediatr 2015; 166:1505.</a></li><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69:7.</a></li><li class="breakAll">American Cancer Society. Cancer Facts and Figures, 2023. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html (Accessed on June 21, 2023).</li><li class="breakAll">American Cancer Society. Cancer Facts and Figures, 2019. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2019.html (Accessed on November 18, 2019).</li><li><a class="nounderline abstract_t">Campbell EH, Reinhart JP, Crum OM, et al. Increasing Incidence and Decreasing Mortality of Cutaneous Melanoma in Middle-Aged Adults: An Epidemiologic Study in Olmsted County, Minnesota. Mayo Clin Proc 2023; 98:713.</a></li><li><a class="nounderline abstract_t">Paulson KG, Gupta D, Kim TS, et al. Age-Specific Incidence of Melanoma in the United States. JAMA Dermatol 2020; 156:57.</a></li><li><a class="nounderline abstract_t">Arnold M, Singh D, Laversanne M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol 2022; 158:495.</a></li><li><a class="nounderline abstract_t">Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009; 27:3.</a></li><li><a class="nounderline abstract_t">Sacchetto L, Zanetti R, Comber H, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer 2018; 92:108.</a></li><li><a class="nounderline abstract_t">Aitken JF, Youlden DR, Baade PD, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. Int J Cancer 2018; 142:1528.</a></li><li class="breakAll">Cancer Australia. Melanoma of the Skin: Melanoma of the skin statistics. https://www.canceraustralia.gov.au/cancer-types/melanoma/statistics (Accessed on June 03, 2022).</li><li><a class="nounderline abstract_t">Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005; 331:481.</a></li><li><a class="nounderline abstract_t">Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch Dermatol 1996; 132:881.</a></li><li><a class="nounderline abstract_t">Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009; 129:1666.</a></li><li><a class="nounderline abstract_t">Waldmann A, Nolte S, Weinstock MA, et al. Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening. Br J Cancer 2012; 106:970.</a></li><li><a class="nounderline abstract_t">Johnson MM, Leachman SA, Aspinwall LG, et al. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag 2017; 4:13.</a></li><li><a class="nounderline abstract_t">Dunlop K, Rankin NM, Smit AK, et al. Acceptability of risk-stratified population screening across cancer types: Qualitative interviews with the Australian public. Health Expect 2021; 24:1326.</a></li><li><a class="nounderline abstract_t">Brunsgaard EK, Wu YP, Grossman D. Melanoma in skin of color: Part I. Epidemiology and clinical presentation. J Am Acad Dermatol 2023; 89:445.</a></li><li><a class="nounderline abstract_t">Qian Y, Johannet P, Sawyers A, et al. The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016). J Am Acad Dermatol 2021; 84:1585.</a></li><li><a class="nounderline abstract_t">Eide MJ, Weinstock MA. Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005; 141:477.</a></li><li><a class="nounderline abstract_t">Baade P, Coory M. Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control. Aust N Z J Public Health 2005; 29:383.</a></li><li><a class="nounderline abstract_t">Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012; 66:201.</a></li><li><a class="nounderline abstract_t">Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340:1341.</a></li><li><a class="nounderline abstract_t">Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997; 73:198.</a></li><li><a class="nounderline abstract_t">Bulliard JL, Cox B, Elwood JM. Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand. Cancer Causes Control 1994; 5:234.</a></li><li><a class="nounderline abstract_t">Pennello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiol Biomarkers Prev 2000; 9:291.</a></li><li><a class="nounderline abstract_t">Kricker A, Armstrong BK, Goumas C, et al. Ambient UV, personal sun exposure and risk of multiple primary melanomas. Cancer Causes Control 2007; 18:295.</a></li><li><a class="nounderline abstract_t">Buckel TB, Goldstein AM, Fraser MC, et al. Recent tanning bed use: a risk factor for melanoma. Arch Dermatol 2006; 142:485.</a></li><li><a class="nounderline abstract_t">Noonan FP, Zaidi MR, Wolnicka-Glubisz A, et al. Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun 2012; 3:884.</a></li><li><a class="nounderline abstract_t">Premi S, Wallisch S, Mano CM, et al. Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science 2015; 347:842.</a></li><li><a class="nounderline abstract_t">Viros A, Sanchez-Laorden B, Pedersen M, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature 2014; 511:478.</a></li><li><a class="nounderline abstract_t">Melnik BC, John SM, Carrera-Bastos P, Schmitz G. MicroRNA-21-Enriched Exosomes as Epigenetic Regulators in Melanomagenesis and Melanoma Progression: The Impact of Western Lifestyle Factors. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Nelemans PJ, Groenendal H, Kiemeney LA, et al. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 1993; 101:252.</a></li><li><a class="nounderline abstract_t">Elwood JM, Gallagher RP, Hill GB, Pearson JC. Cutaneous melanoma in relation to intermittent and constant sun exposure--the Western Canada Melanoma Study. Int J Cancer 1985; 35:427.</a></li><li><a class="nounderline abstract_t">Zanetti R, Rosso S, Martinez C, et al. Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study. Br J Cancer 2006; 94:743.</a></li><li><a class="nounderline abstract_t">Gandini S, Montella M, Ayala F, et al. Sun exposure and melanoma prognostic factors. Oncol Lett 2016; 11:2706.</a></li><li><a class="nounderline abstract_t">Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006; 24:3172.</a></li><li><a class="nounderline abstract_t">Ghiasvand R, Robsahm TE, Green AC, et al. Association of Phenotypic Characteristics and UV Radiation Exposure With Risk of Melanoma on Different Body Sites. JAMA Dermatol 2019; 155:39.</a></li><li><a class="nounderline abstract_t">Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev 2014; 23:1080.</a></li><li><a class="nounderline abstract_t">Cooke KR, Fraser J. Migration and death from malignant melanoma. Int J Cancer 1985; 36:175.</a></li><li><a class="nounderline abstract_t">Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73:75.</a></li><li><a class="nounderline abstract_t">Young AR. The sunburn cell. Photodermatol 1987; 4:127.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Use of indoor tanning devices by adults--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61:323.</a></li><li><a class="nounderline abstract_t">Guy GP Jr, Berkowitz Z, Watson M, et al. Indoor tanning among young non-Hispanic white females. JAMA Intern Med 2013; 173:1920.</a></li><li><a class="nounderline abstract_t">Bowers JM, Geller AC, Schofield E, et al. Indoor Tanning Trends Among US Adults, 2007-2018. Am J Public Health 2020; 110:823.</a></li><li><a class="nounderline abstract_t">El Ghissassi F, Baan R, Straif K, et al. A review of human carcinogens--part D: radiation. Lancet Oncol 2009; 10:751.</a></li><li><a class="nounderline abstract_t">Wehner MR, Chren MM, Nameth D, et al. International prevalence of indoor tanning: a systematic review and meta-analysis. JAMA Dermatol 2014; 150:390.</a></li><li><a class="nounderline abstract_t">International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.</a></li><li><a class="nounderline abstract_t">Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. J Am Acad Dermatol 2014; 70:847.</a></li><li><a class="nounderline abstract_t">Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012; 345:e4757.</a></li><li><a class="nounderline abstract_t">Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:562.</a></li><li><a class="nounderline abstract_t">Swerdlow AJ, Weinstock MA. Do tanning lamps cause melanoma? An epidemiologic assessment. J Am Acad Dermatol 1998; 38:89.</a></li><li><a class="nounderline abstract_t">Seddon JM, Gragoudas ES, Glynn RJ, et al. Host factors, UV radiation, and risk of uveal melanoma. A case-control study. Arch Ophthalmol 1990; 108:1274.</a></li><li><a class="nounderline abstract_t">Vajdic CM, Kricker A, Giblin M, et al. Artificial ultraviolet radiation and ocular melanoma in Australia. Int J Cancer 2004; 112:896.</a></li><li><a class="nounderline abstract_t">Schmidt-Pokrzywniak A, Jöckel KH, Bornfeld N, et al. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study. Ophthalmology 2009; 116:340.</a></li><li><a class="nounderline abstract_t">An S, Kim K, Moon S, et al. Indoor Tanning and the Risk of Overall and Early-Onset Melanoma and Non-Melanoma Skin Cancer: Systematic Review and Meta-Analysis. Cancers (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Lazovich D, Isaksson Vogel R, Weinstock MA, et al. Association Between Indoor Tanning and Melanoma in Younger Men and Women. JAMA Dermatol 2016; 152:268.</a></li><li><a class="nounderline abstract_t">Schneider S, Krämer H. Who uses sunbeds? A systematic literature review of risk groups in developed countries. J Eur Acad Dermatol Venereol 2010; 24:639.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Malvy D, Mauger E, et al. Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7200 French adults. J Eur Acad Dermatol Venereol 2008; 22:186.</a></li><li><a class="nounderline abstract_t">Miyamura Y, Coelho SG, Schlenz K, et al. The deceptive nature of UVA tanning versus the modest protective effects of UVB tanning on human skin. Pigment Cell Melanoma Res 2011; 24:136.</a></li><li><a class="nounderline abstract_t">Vogel RI, Ahmed RL, Nelson HH, et al. Exposure to indoor tanning without burning and melanoma risk by sunburn history. J Natl Cancer Inst 2014; 106:dju112.</a></li><li><a class="nounderline abstract_t">Stern RS, PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44:755.</a></li><li><a class="nounderline abstract_t">Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040.</a></li><li><a class="nounderline abstract_t">Purdue MP, From L, Armstrong BK, et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14:2015.</a></li><li><a class="nounderline abstract_t">Pampena R, Kyrgidis A, Lallas A, et al. A meta-analysis of nevus-associated melanoma: Prevalence and practical implications. J Am Acad Dermatol 2017; 77:938.</a></li><li><a class="nounderline abstract_t">Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806.</a></li><li><a class="nounderline abstract_t">Olsen CM, Zens MS, Stukel TA, et al. Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis. Int J Cancer 2009; 124:937.</a></li><li><a class="nounderline abstract_t">Cho E, Rosner BA, Colditz GA. Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev 2005; 14:1241.</a></li><li><a class="nounderline abstract_t">Caini S, Gandini S, Sera F, et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009; 45:3054.</a></li><li><a class="nounderline abstract_t">Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277:1439.</a></li><li><a class="nounderline abstract_t">Veierød MB, Weiderpass E, Thörn M, et al. A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women. J Natl Cancer Inst 2003; 95:1530.</a></li><li class="breakAll">Barnhill RL. Melanocytic proliferations with architectural disorder and cytologic atypia (melanocytic dysplasia and atypical nevi). In: Pathology of Melanocytic Nevi and Melanoma, Barnhill RL (Ed), Butterworth-Heinemann, 1995. p.169.</li><li><a class="nounderline abstract_t">Chaudru V, Chompret A, Bressac-de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004; 96:785.</a></li><li class="breakAll">Tsao HK, Pehamberger H, Sober AJ. Precursor lesions and markers for increased risk of melanoma. In: Cutaneous Melanoma, Balch CM, Houghton AN, Sober AJ, Soong SJ (Eds), Quality Medical Publishing Inc, 1998. p.65.</li><li><a class="nounderline abstract_t">Bataille V, Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73:1605.</a></li><li><a class="nounderline abstract_t">Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer Prev Res (Phila) 2010; 3:233.</a></li><li><a class="nounderline abstract_t">Ribero S, Zugna D, Osella-Abate S, et al. Prediction of high naevus count in a healthy U.K. population to estimate melanoma risk. Br J Dermatol 2016; 174:312.</a></li><li><a class="nounderline abstract_t">Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case-control study. Int J Cancer 1998; 77:843.</a></li><li><a class="nounderline abstract_t">Rivers JK. Is there more than one road to melanoma? Lancet 2004; 363:728.</a></li><li><a class="nounderline abstract_t">Cust AE, Drummond M, Bishop DT, et al. Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure. J Eur Acad Dermatol Venereol 2019; 33:1874.</a></li><li><a class="nounderline abstract_t">Vourc'h-Jourdain M, Martin L, Barbarot S, aRED. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013; 68:493.</a></li><li><a class="nounderline abstract_t">Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005; 41:28.</a></li><li><a class="nounderline abstract_t">Lynch HT, Frichot BC 3rd, Lynch JF. Familial atypical multiple mole-melanoma syndrome. J Med Genet 1978; 15:352.</a></li><li><a class="nounderline abstract_t">Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114:732.</a></li><li><a class="nounderline abstract_t">Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003; 349:2233.</a></li><li><a class="nounderline abstract_t">Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010; 146:265.</a></li><li><a class="nounderline abstract_t">Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003; 97:639.</a></li><li><a class="nounderline abstract_t">Levi F, Randimbison L, Te VC, La Vecchia C. High constant incidence rates of second cutaneous melanomas. Int J Cancer 2005; 117:877.</a></li><li><a class="nounderline abstract_t">Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010; 62:757.</a></li><li><a class="nounderline abstract_t">Beroukhim K, Pourang A, Eisen DB. Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study. J Am Acad Dermatol 2020; 82:683.</a></li><li><a class="nounderline abstract_t">Ni Y, Watts CG, Scolyer RA, et al. Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort. Br J Dermatol 2023; 188:814.</a></li><li><a class="nounderline abstract_t">Chen T, Fallah M, Försti A, et al. Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas. JAMA Dermatol 2015; 151:607.</a></li><li><a class="nounderline abstract_t">Pomerantz H, Huang D, Weinstock MA. Risk of subsequent melanoma after melanoma in situ and invasive melanoma: a population-based study from 1973 to 2011. J Am Acad Dermatol 2015; 72:794.</a></li><li><a class="nounderline abstract_t">Gassenmaier M, Stec T, Keim U, et al. Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry. J Eur Acad Dermatol Venereol 2019; 33:63.</a></li><li><a class="nounderline abstract_t">Greene MH. The genetics of hereditary melanoma and nevi. 1998 update. Cancer 1999; 86:2464.</a></li><li><a class="nounderline abstract_t">Fu T, Swetter SM, Tao L, et al. Characterizing subsequent primary melanomas (SPM) in adolescents and young adults: A population-based study from 1973 to 2011. J Am Acad Dermatol 2016; 74:181.</a></li><li><a class="nounderline abstract_t">Siskind V, Hughes MC, Palmer JM, et al. Nevi, family history, and fair skin increase the risk of second primary melanoma. J Invest Dermatol 2011; 131:461.</a></li><li><a class="nounderline abstract_t">Baumert J, Schmidt M, Giehl KA, et al. Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype. Melanoma Res 2009; 19:24.</a></li><li><a class="nounderline abstract_t">Rivers JK. Melanoma. Lancet 1996; 347:803.</a></li><li><a class="nounderline abstract_t">Carey WP Jr, Thompson CJ, Synnestvedt M, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994; 74:3118.</a></li><li><a class="nounderline abstract_t">Soura E, Eliades PJ, Shannon K, et al. Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol 2016; 74:395.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Dracopoli NC, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994; 54:489.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007; 44:99.</a></li><li><a class="nounderline abstract_t">Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970.</a></li><li><a class="nounderline abstract_t">Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11:328.</a></li><li><a class="nounderline abstract_t">Mitra D, Luo X, Morgan A, et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012; 491:449.</a></li><li><a class="nounderline abstract_t">Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst 2005; 97:998.</a></li><li><a class="nounderline abstract_t">Wendt J, Rauscher S, Burgstaller-Muehlbacher S, et al. Human Determinants and the Role of Melanocortin-1 Receptor Variants in Melanoma Risk Independent of UV Radiation Exposure. JAMA Dermatol 2016; 152:776.</a></li><li><a class="nounderline abstract_t">Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43:1018.</a></li><li><a class="nounderline abstract_t">Gerami P, Yélamos O, Lee CY, et al. Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation. JAMA Dermatol 2015; 151:1235.</a></li><li><a class="nounderline abstract_t">Piris A, Mihm MC Jr, Hoang MP. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum Pathol 2015; 46:239.</a></li><li><a class="nounderline abstract_t">Walpole S, Pritchard AL, Cebulla CM, et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst 2018; 110:1328.</a></li><li><a class="nounderline abstract_t">Marghoob AA, Slade J, Salopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995; 75:707.</a></li><li><a class="nounderline abstract_t">Kahn HS, Tatham LM, Patel AV, et al. Increased cancer mortality following a history of nonmelanoma skin cancer. JAMA 1998; 280:910.</a></li><li><a class="nounderline abstract_t">Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012; 87:991.</a></li><li><a class="nounderline abstract_t">Brewer JD, Christenson LJ, Weaver AL, et al. Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol 2011; 147:790.</a></li><li><a class="nounderline abstract_t">Hollenbeak CS, Todd MM, Billingsley EM, et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005; 104:1962.</a></li><li><a class="nounderline abstract_t">Ascha M, Ascha MS, Tanenbaum J, Bordeaux JS. Risk Factors for Melanoma in Renal Transplant Recipients. JAMA Dermatol 2017; 153:1130.</a></li><li><a class="nounderline abstract_t">Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274.</a></li><li><a class="nounderline abstract_t">Jiang AJ, Rambhatla PV, Eide MJ. Socioeconomic and lifestyle factors and melanoma: a systematic review. Br J Dermatol 2015; 172:885.</a></li><li><a class="nounderline abstract_t">Ward EM, Burnett CA, Ruder A, Davis-King K. Industries and cancer. Cancer Causes Control 1997; 8:356.</a></li><li><a class="nounderline abstract_t">Hercberg S, Ezzedine K, Guinot C, et al. Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 2007; 137:2098.</a></li><li><a class="nounderline abstract_t">Asgari MM, Maruti SS, Kushi LH, White E. Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study. Arch Dermatol 2009; 145:879.</a></li><li><a class="nounderline abstract_t">Millen AE, Tucker MA, Hartge P, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042.</a></li><li><a class="nounderline abstract_t">Cattaruzza MS, Pisani D, Fidanza L, et al. 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies. Eur J Cancer Prev 2019; 28:203.</a></li><li><a class="nounderline abstract_t">Liyanage UE, Law MH, Melanoma Meta-analysis Consortium, et al. Is there a causal relationship between vitamin D and melanoma risk? A Mendelian randomization study. Br J Dermatol 2020; 182:97.</a></li><li><a class="nounderline abstract_t">Yamauchi T, Shangraw S, Zhai Z, et al. Alcohol as a Non-UV Social-Environmental Risk Factor for Melanoma. Cancers (Basel) 2022; 14.</a></li><li><a class="nounderline abstract_t">Liu J, Shen B, Shi M, Cai J. Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study. PLoS One 2016; 11:e0147056.</a></li><li><a class="nounderline abstract_t">Wang J, Li X, Zhang D. Coffee consumption and the risk of cutaneous melanoma: a meta-analysis. Eur J Nutr 2016; 55:1317.</a></li><li><a class="nounderline abstract_t">Yew YW, Lai YC, Schwartz RA. Coffee Consumption and Melanoma: A Systematic Review and Meta-Analysis of Observational Studies. Am J Clin Dermatol 2016; 17:113.</a></li><li><a class="nounderline abstract_t">Wu S, Han J, Song F, et al. Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma. Epidemiology 2015; 26:898.</a></li><li><a class="nounderline abstract_t">Conney AH, Lu YP, Lou YR, et al. Mechanisms of Caffeine-Induced Inhibition of UVB Carcinogenesis. Front Oncol 2013; 3:144.</a></li><li><a class="nounderline abstract_t">Ravi D, Muniyappa H, Das KC. Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism. Mol Cell Biochem 2008; 308:193.</a></li><li><a class="nounderline abstract_t">Caini S, Masala G, Saieva C, et al. Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2017; 140:2246.</a></li><li><a class="nounderline abstract_t">Wu S, Han J, Feskanich D, et al. Citrus Consumption and Risk of Cutaneous Malignant Melanoma. J Clin Oncol 2015; 33:2500.</a></li><li><a class="nounderline abstract_t">Sayre RM, Dowdy JC. The increase in melanoma: are dietary furocoumarins responsible? Med Hypotheses 2008; 70:855.</a></li><li><a class="nounderline abstract_t">Merimsky O, Inbar M. Cigarette smoking and skin cancer. Clin Dermatol 1998; 16:585.</a></li><li><a class="nounderline abstract_t">Sondermeijer L, Lamboo LGE, de Waal AC, et al. Cigarette Smoking and the Risk of Cutaneous Melanoma: A Case-Control Study. Dermatology 2020; 236:228.</a></li><li><a class="nounderline abstract_t">Pfahlberg A, Hassan K, Wille L, et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997; 25:309.</a></li><li><a class="nounderline abstract_t">Gandini S, Iodice S, Koomen E, et al. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer 2011; 47:2607.</a></li><li><a class="nounderline abstract_t">Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011; 103:1469.</a></li><li><a class="nounderline abstract_t">Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2020; 146:3267.</a></li><li><a class="nounderline abstract_t">Kowalzick L, Eickenscheidt L, Komar M, Schaarschmidt E. [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma]. Hautarzt 2009; 60:655.</a></li><li><a class="nounderline abstract_t">Khan I, Rahman L, McKenna DB. Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009; 34:524.</a></li><li><a class="nounderline abstract_t">Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007; 56:S65.</a></li><li><a class="nounderline abstract_t">Manganoni AM, Zane C, Pavoni L, et al. Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report. Dermatol Online J 2011; 17:12.</a></li><li><a class="nounderline abstract_t">Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895.</a></li><li><a class="nounderline abstract_t">Carlos G, Anforth R, Clements A, et al. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatol 2015; 151:1103.</a></li><li><a class="nounderline abstract_t">Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med 2014; 174:964.</a></li><li><a class="nounderline abstract_t">Loeb S, Folkvaljon Y, Lambe M, et al. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. JAMA 2015; 313:2449.</a></li><li><a class="nounderline abstract_t">Matthews A, Langan SM, Douglas IJ, et al. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink. PLoS Med 2016; 13:e1002037.</a></li><li><a class="nounderline abstract_t">Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300.</a></li><li><a class="nounderline abstract_t">Olsen JH, Friis S, Frederiksen K, et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005; 92:201.</a></li><li><a class="nounderline abstract_t">Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006; 17:582.</a></li><li><a class="nounderline abstract_t">Bertoni JM, Arlette JP, Fernandez HH, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010; 67:347.</a></li><li><a class="nounderline abstract_t">Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers. J Neural Transm (Vienna) 2009; 116:1503.</a></li><li><a class="nounderline abstract_t">Wirdefeldt K, Weibull CE, Chen H, et al. Parkinson's disease and cancer: A register-based family study. Am J Epidemiol 2014; 179:85.</a></li><li><a class="nounderline abstract_t">Dalvin LA, Damento GM, Yawn BP, et al. Parkinson Disease and Melanoma: Confirming and Reexamining an Association. Mayo Clin Proc 2017; 92:1070.</a></li><li><a class="nounderline abstract_t">Zanetti R, Loria D, Rosso S. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 2006; 16:201.</a></li><li><a class="nounderline abstract_t">Olsen JH, Tangerud K, Wermuth L, et al. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007; 22:1252.</a></li><li><a class="nounderline abstract_t">Kvaskoff M, Mesrine S, Fournier A, et al. Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women. Arch Intern Med 2007; 167:2061.</a></li><li><a class="nounderline abstract_t">Somigliana E, Vigano' P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101:331.</a></li><li><a class="nounderline abstract_t">Li WQ, Qureshi AA, Ma J, et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol 2013; 31:4394.</a></li><li><a class="nounderline abstract_t">Vuong K, Armstrong BK, Drummond M, et al. Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines. Br J Dermatol 2020; 182:1262.</a></li><li><a class="nounderline abstract_t">Cust AE, Badcock C, Smith J, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol 2020; 182:1148.</a></li><li><a class="nounderline abstract_t">Kaiser I, Pfahlberg AB, Uter W, et al. Risk Prediction Models for Melanoma: A Systematic Review on the Heterogeneity in Model Development and Validation. Int J Environ Res Public Health 2020; 17.</a></li></ol></div><div id="topicVersionRevision">Topic 4844 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034049" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17416855" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24210187" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25866386" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Melanoma Incidence in Children and Adolescents: Decreasing Trends in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30620402" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cancer statistics, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30620402" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cancer statistics, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30620402" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cancer statistics, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37137643" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Increasing Incidence and Decreasing Mortality of Cutaneous Melanoma in Middle-Aged Adults: An Epidemiologic Study in Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31721989" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Age-Specific Incidence of Melanoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35353115" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095149" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Melanoma epidemiology and trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395684" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Trends in incidence of thick, thin and in situ melanoma in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29105744" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29105744" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16081427" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Skin biopsy rates and incidence of melanoma: population based ecological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8712837" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The melanoma epidemic. Is increased surveillance the solution or the problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131946" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Increasing burden of melanoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22294187" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Skin cancer screening participation and impact on melanoma incidence in Germany--an observational study on incidence trends in regions with and without population-based screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28758010" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33974726" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acceptability of risk-stratified population screening across cancer types: Qualitative interviews with the Australian public.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35533771" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Melanoma in skin of color: Part I. Epidemiology and clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32861710" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837865" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16222938" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Trends in melanoma mortality in Australia: 1950-2002 and their implications for melanoma control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22074699" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic skin cancer screening in Northern Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10219070" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The pathogenesis of melanoma induced by ultraviolet radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9335442" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Melanoma and sun exposure: an overview of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8061171" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Latitude gradients in melanoma incidence and mortality in the non-Maori population of New Zealand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10750668" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17206532" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ambient UV, personal sun exposure and risk of multiple primary melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16618869" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Recent tanning bed use: a risk factor for melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22673911" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25700512" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24919155" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32751207" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : MicroRNA-21-Enriched Exosomes as Epigenetic Regulators in Melanomagenesis and Melanoma Progression: The Impact of Western Lifestyle Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404764" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3988369" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cutaneous melanoma in relation to intermittent and constant sun exposure--the Western Canada Melanoma Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495934" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case-case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27073541" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Sun exposure and melanoma prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16809740" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Anatomic site, sun exposure, and risk of cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30477003" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Association of Phenotypic Characteristics and UV Radiation Exposure With Risk of Melanoma on Different Body Sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24876226" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4018910" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Migration and death from malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6588237" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3317295" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The sunburn cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22572978" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of indoor tanning devices by adults--United States, 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23959651" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Indoor tanning among young non-Hispanic white females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298165" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Indoor Tanning Trends Among US Adults, 2007-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19655431" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A review of human carcinogens--part D: radiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477278" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : International prevalence of indoor tanning: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17131335" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629998" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The association of indoor tanning and melanoma in adults: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22833605" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15767329" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tanning beds, sunlamps, and risk of cutaneous malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9448211" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Do tanning lamps cause melanoma? An epidemiologic assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2400347" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Host factors, UV radiation, and risk of uveal melanoma. A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15386378" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Artificial ultraviolet radiation and ocular melanoma in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091418" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34885049" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Indoor Tanning and the Risk of Overall and Early-Onset Melanoma and Non-Melanoma Skin Cancer: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26818409" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Association Between Indoor Tanning and Melanoma in Younger Men and Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015180" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Who uses sunbeds? A systematic literature review of risk groups in developed countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18211412" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7200 French adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979596" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The deceptive nature of UVA tanning versus the modest protective effects of UVB tanning on human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24872541" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Exposure to indoor tanning without burning and melanoma risk by sunburn history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11312420" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The risk of melanoma in association with long-term exposure to PUVA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16125929" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16103454" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28864306" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A meta-analysis of nevus-associated melanoma: Prevalence and practical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783935" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19035450" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nevus density and melanoma risk in women: a pooled analysis to test the divergent pathway hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894679" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Risk factors for melanoma by body site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19545997" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145715" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14559875" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14559875" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A prospective study of pigmentation, sun exposure, and risk of cutaneous malignant melanoma in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150307" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150307" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664138" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20086181" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26479165" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Prediction of high naevus count in a healthy U.K. population to estimate melanoma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9714052" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : p53 expression and risk factors for cutaneous melanoma: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15005091" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Is there more than one road to melanoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31087403" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182059" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15617989" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/739524" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Familial atypical multiple mole-melanoma syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/646394" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657431" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinical practice. Dysplastic nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20231496" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Increased risk of second primary cancers after a diagnosis of melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548605" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15957164" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : High constant incidence rates of second cutaneous melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20223559" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31626886" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36946230" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671687" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Risk of Next Melanoma in Patients With Familial and Sporadic Melanoma by Number of Previous Melanomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25769192" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk of subsequent melanoma after melanoma in situ and invasive melanoma: a population-based study from 1973 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30051517" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Incidence and characteristics of thick second primary melanomas: a study of the German Central Malignant Melanoma Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10630172" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The genetics of hereditary melanoma and nevi. 1998 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26702802" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Characterizing subsequent primary melanomas (SPM) in adolescents and young adults: A population-based study from 1973 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20944647" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Nevi, family history, and fair skin increase the risk of second primary melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19430403" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622339" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7982177" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Dysplastic nevi as a melanoma risk factor in patients with familial melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26892650" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8116618" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905682" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666916" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7581459" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23123854" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998953" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27050141" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Human Determinants and the Role of Melanocortin-1 Receptor Variants in Melanoma Risk Independent of UV Radiation Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21874003" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Germline mutations in BAP1 predispose to melanocytic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154183" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25479927" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30517737" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7804999" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9739976" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Increased cancer mortality following a history of nonmelanoma skin cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036673" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Melanoma in immunosuppressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768478" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187269" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Increased incidence of melanoma in renal transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28746700" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Risk Factors for Melanoma in Renal Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8600636" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Malignant melanoma in organ allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25354495" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Socioeconomic and lifestyle factors and melanoma: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9498899" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Industries and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709449" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Antioxidant supplementation increases the risk of skin cancers in women but not in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687417" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Antioxidant supplementation and risk of incident melanomas: results of a large prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184262" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Diet and melanoma in a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29438161" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : 25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31218665" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Is there a causal relationship between vitamin D and melanoma risk? A Mendelian randomization study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36291794" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Alcohol as a Non-UV Social-Environmental Risk Factor for Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26816289" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Higher Caffeinated Coffee Intake Is Associated with Reduced Malignant Melanoma Risk: A Meta-Analysis Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26695410" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Coffee consumption and the risk of cutaneous melanoma: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26547919" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Coffee Consumption and Melanoma: A Systematic Review and Meta-Analysis of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172864" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23785666" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Mechanisms of Caffeine-Induced Inhibition of UVB Carcinogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932622" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Caffeine inhibits UV-mediated NF-kappaB activation in A2058 melanoma cells: an ATM-PKCdelta-p38 MAPK-dependent mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28218395" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26124488" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Citrus Consumption and Risk of Cutaneous Malignant Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17881138" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : The increase in melanoma: are dietary furocoumarins responsible?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9787970" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Cigarette smoking and skin cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31505496" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Cigarette Smoking and the Risk of Cutaneous Melanoma: A Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9553446" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21620689" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21878677" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31506954" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19280165" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : [Long term treatment of psoriasis with TNF-alpha antagonists. Occurrence of malignant melanoma].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196307" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Primary cutaneous melanoma: a complication of infliximab treatment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434043" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21906492" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Cutaneous melanoma in patients in treatment with biological therapy: review of the literature and case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21885875" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26200476" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24710960" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26103029" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27299522" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083676" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15583688" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Atypical cancer pattern in patients with Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16837822" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Malignant melanoma and other types of cancer preceding Parkinson disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212233" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19789839" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : The particular relationship between Parkinson's disease and malignancy: a focus on skin cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24142916" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Parkinson's disease and cancer: A register-based family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688464" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Parkinson Disease and Melanoma: Confirming and Reexamining an Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16718266" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534943" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Treatment with levodopa and risk for malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954799" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473398" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24190118" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Personal history of prostate cancer and increased risk of incident melanoma in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31378928" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31520533" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : A risk prediction model for the development of subsequent primary melanoma in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33126677" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Risk Prediction Models for Melanoma: A Systematic Review on the Heterogeneity in Model Development and Validation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
